Karin Jooss
Hoofd Techniek/Wetenschap/O&O bij GRITSTONE BIO, INC.
Vermogen: 561 009 $ op 30-04-2024
Actieve functies van Karin Jooss
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GRITSTONE BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 13-04-2016 | - |
| FATE THERAPEUTICS, INC. | Directeur/Bestuurslid | 14-03-2019 | - |
| Independent Dir/Board Member | 14-03-2019 | - |
Loopbaan van Karin Jooss
Eerdere bekende functies van Karin Jooss
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01-05-2009 | 01-04-2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Hoofd Techniek/Wetenschap/O&O | 01-07-2001 | 01-04-2009 |
Opleiding van Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Duitsland | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GRITSTONE BIO, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Beurs
- Insiders
- Karin Jooss
- Ervaring
